Abstract
Introduction

102
Metabolic syndrome (MetS), also known as syndrome X, is a cluster of several cardiometabolic 103 risk factors including abdominal adiposity, hyperglycemia, hypertriglyceridemia, low HDL-C 104 and hypertension (1, 2) . MetS prevalence ranges between 10 to 84 % worldwide. According to 105 Azimi-Nezhad et al., 55.0% of Iranian females and 30.1% of Iranian males have Mets (3).
106
Insulin resistance and visceral adiposity are the key factors underlying MetS pathophysiology.
107
Visceral adipose tissue acts as an endocrine organ and releases different kinds of cytokines 108 named adipokines. These adipokines mediate multiple processes such as insulin sensitivity, 109 oxidative stress and inflammation; hence their imbalance could contribute to the development of 110 type 2 diabetes mellitus and atherosclerosis.
111
Adiponectin and leptin are the most studied adipokines, and their levels are known to be altered resistance (9, 10). Elevated plasma levels of leptin have been suggested as an independent risk 120 factor for coronary artery disease (10, 11).
121
Curcumin is the orange-yellow pigment extracted from the famous spice turmeric. Curcumin is a 122 unique phytochemical owing to its numerous molecular targets and diversity of biological Interestingly, curcumin could modify almost all features of MetS (28). There is evidence 128 indicating that curcumin lowers plasma levels of total cholesterol, LDL-cholesterol (LDL-C), 129 triglyceride and glucose, and increases those of [29] [30] [31] [32] [33] 
Materials and methods
140
Subjects
141
This study is a post-hoc analysis performed on the samples obtained from our previous 
150
Exclusion criteria were pregnancy or breastfeeding, lack of compliance with the study 151 medication (defined as not using the medication for > 1 week), participation in a concomitant 152 trial, hypersensitivity to the study medication, presence of malignancies and impossibility to give 153 informed consent. The study protocol was given approval by the institutional Ethics Committee 154 and written informed consent was obtained from participants. 
Study design
157
This study was designed as a randomized double-blind placebo-controlled trial with a parallel-158 group design. Subjects who met the inclusion criteria were randomly assigned to either curcumin non-normally distributed data). Categorical variables were compared using Chi-square test.
187
Bivariate correlations between changes in serum levels of leptin, adiponectin and 188 leptin:adiponectin ratio were performed using Pearson's (for normally distributed data) and 
Results
209
One hundred and seventeen subjects met the inclusion criteria and were assigned to either 210 curcumin (n = 59) or placebo (n = 58). One hundred subjects completed the trial. Nine subjects 211 in the curcumin group and eight subjects in the placebo group did not complete the study due to 212 loss to follow-up (Figure 1) . adjustment for baseline differences in BMI, serum glucose and HbA1c concentrations (p<0.001).
239
As reported in our previous report (17), curcumin were well-tolerated during the study. There in serum adiponectin and leptin concentrations in either of the studied groups ( and leptin in this study is consistent with the reduction in serum glucose of the same individuals 298 reproted previously (63). In our previous report, however, no significant effect could be detected 299 in HbA1c which might be due to the short duration of follow-up.
300
Aside from insulin resistance, dyslipidemia is another prevalent feature of MetS, commonly lipid-modifying effect of curcumin has also been reported in some other trials (19, 50, 61) .
306
As reported previously (16, 17), curcumin supplementation was safe in this trial. Curcumin has 307 been approved by US FDA as a "generally recognized as safe" supplement, and its tolerability indirect biomarkers of insulin resistance, insulin resistance was not measured in this study.
330
In conclusion, the present trial provided the first evidence on the improvement of circulating 
